AI Article Synopsis
- Cutaneous melanoma (CM) is a type of skin cancer linked to immune system activity and has poor outcomes in advanced stages.
- A study of 51 CM patients and 30 healthy individuals revealed significant differences in inflammatory markers and platelet activation profiles between the groups.
- Findings indicate that high levels of certain immune markers and platelet-leukocyte aggregates may be tied to worse prognoses in CM patients, suggesting an immunosuppressive environment that could aid tumor progression.
Article Abstract
Background: Cutaneous melanoma (CM) is a malignancy with a variable incidence worldwide and a poor advanced-stage prognosis. Melanoma growth is closely associated with the immune system.
Methods: A cross-sectional study was performed on CM patients admitted at the Hospital de Cancer de Pernambuco (HCP) between 2015 and 2018. Fifty-one CM patients were included, and 30 healthy individuals. The study aimed to evaluate the association of platelet activation mechanisms and inflammatory response in patients with cutaneous melanoma.
Results: Elevated serum IL10 and low serum TNF levels in CM patients compared to controls (p < 0.05). High IL6 levels in patients with negative lymph nodes LN (-) compared to positive lymph nodes group (LN +, p = 0.0005). Low RANTES levels in patients compared to controls (p < 0.05). Elevated levels of platelet-lymphocyte (PLA), platelet-monocytes (PMA), and platelet-neutrophils (PNA) aggregates were observed in patients compared to controls (p < 0.05). CM patients with stage II had lower PMA levels than stages I and III (p < 0.05). High PMA levels were observed in patients with LN (+) compared to the LN (-) group (p < 0.0001). Patients with SSM had high levels of sCD40L and sCD62P compared to controls (p < 0.05)). High sCD40L levels in stage II compared to the stage III group, and sCD62P in stages I and II compared to the stage III group (p < 0.05). High sCD62P levels in patients with LN (-) compared to the group LN (+) (p < 0.05).
Conclusion: It was observed the immunosuppressive profile in CM may favor tumor progression. High levels of platelet-leukocyte aggregates, sCD40L, and sCD62P may be associated with the worst prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.27748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cryoshocked Adipocytes Mediated Dual-Modal Strategy Combining Photodynamic Therapy and Triptolide Palmitate for Pulmonary Metastatic Melanoma Treatment.
Adv Sci (Weinh)
January 2025
Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Pulmonary metastasis represents one of the most prevalent forms of metastasis in advanced melanoma, with mortality rates reaching 70%. Current treatments including chemotherapy, targeted therapy, and immunotherapy frequently exhibit limited efficacy or present high costs. To address these clinical needs, this study presents a biomimetic drug delivery system (Ce6-pTP-CsA) utilizing cryoshocked adipocytes (CsA) encapsulating the prodrug triptolide palmitate (pTP) and the photosensitizer Ce6, exploiting the characteristic of tumor cells to recruit and lipolyze adipocytes for energy.
View Article and Find Full Text PDFBeta-Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random-Effects Meta-Analysis.
Pigment Cell Melanoma Res
January 2025
Dermatology Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia.
Beta-blockers have generated an exciting discourse for their potential as a cheap, safe, and effective adjunctive therapy for cutaneous melanoma patients, but the field remains murky. This systematic review investigates the association between beta-blocker use and survival outcomes in cutaneous melanoma patients. We reviewed 12 studies with 21,582 patients in a network meta-analysis and found a benefit between beta-blocker use and disease-free survival but no other significant association for melanoma-specific or overall survival.
View Article and Find Full Text PDFEmpowering physical therapists in the fight against melanoma.
Arch Dermatol Res
January 2025
Department of Dermatology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Loss of NF1 accelerates uveal and intra-dermal melanoma tumorigenesis and oncogenic GNAQ transforms Schwann cells.
Cancer Res Commun
January 2025
University of British Columbia, Vancouver, BC, Canada.
NF1 encodes the multifunctional tumour suppressor protein, neurofibromin, which is best known for its causative role in Neurofibromatosis type 1 and in regulating MAPK signaling. Neurofibromin, in a context-specific manner, is involved in various tumorigenic processes, including those in melanocytes. This study investigated whether NF1 loss can collaborate with oncogenic GNAQ to promote melanoma in the dermis or eyes, where the G alpha q pathway is almost always activated.
View Article and Find Full Text PDF[Evaluation of the impact of a comprehensive rehabilitation program on improving nutritional status, psychoemotional signs and adverse events in patients with melanoma after surgical treatment].
Khirurgiia (Mosk)
January 2025
Medsi Clinical Hospital in Otradnoye of the Joint-Stock Company "Medsi Group of Companies", Krasnogorsk, Russia.
Unlabelled: The purpose of the study: to evaluate the impact of a comprehensive rehabilitation program on physical health indicators, such as weight restoration and improvement of functional capabilities of patients, psychoemotional state of patients, reduction of complications after surgical treatment.
Material And Methods: Observations were conducted on 148 patients diagnosed with melanoma of various localizations, who were divided into two groups by simple randomization: study (=77) and control (=71). The study group received surgical treatment in combination with rehabilitation programs (psychotherapy, nutritional support, general magnetic therapy), while the control group received only standard surgical treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!